Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Denali Therapeutics ( (DNLI) ) has provided an announcement.
Denali Therapeutics has announced that its partner Sanofi has discontinued the Phase 2 study of oditrasertib for multiple sclerosis due to the drug failing to meet the primary and key secondary outcomes. This development may be of interest to those tracking the progress and potential impact of Denali’s pharmaceutical endeavors within the stock market.
See more insights into DNLI stock on TipRanks’ Stock Analysis page.